The FDA approved Zanvastro, containing zilganersen, as the first treatment specifically developed for Alexander disease, a rare genetic disorder affecting the brain and nervous system. Administered by spinal injection every three months, the therapy targets underlying disease mechanisms and was associated with Read More
